Thromboembolism and Janus Kinase Inhibitors

Janus kinase (JAK) inhibitors, the newest disease-modifying anti-rheumatic drugs used to treat rheumatoid arthritis (RA), have been linked with thromboembolic risks for several years. The report by Vallejo-Yagüe et al highlights the risks of thromboembolism with tofacitinib and baricitinib, the firs...

Full description

Saved in:
Bibliographic Details
Published in:Drug safety 2020-09, Vol.43 (9), p.831-833
Main Authors: Ibrahim, Fowzia, Scott, David L.
Format: Article
Language:English
Subjects:
Arthritis
Biological products
Commentary
Conflicts of interest
Drug dosages
Drug Safety and Pharmacovigilance
Inhibitors
Janus kinase
Kinases
Medicine
Medicine & Public Health
Patients
Pharmacology/Toxicology
Prescription drugs
Pulmonary embolisms
Rheumatoid arthritis
Systematic review
Thromboembolism
Thrombosis
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Janus kinase (JAK) inhibitors, the newest disease-modifying anti-rheumatic drugs used to treat rheumatoid arthritis (RA), have been linked with thromboembolic risks for several years. The report by Vallejo-Yagüe et al highlights the risks of thromboembolism with tofacitinib and baricitinib, the first two JAK inhibitors prescribed for RA patients. As with all adverse events, it is crucial to consider the strength of the evidence about their risks, to assess the magnitude of the problem and to refect on the implications for clinical practice. Thromboembolism was identified as a potential clinically important adverse event with JAK inhibitors during the approval process for baricitinib. Several subsequent reports and reviews have considered the strength of the evidence about this risk and the overall size of the problem. There are a number of complexities involved. Ibrahim and Scott conclude that there is strong evidence from a range of sources that JAK inhibitors increase the risk of thromboembolism.
ISSN:0114-5916
1179-1942
DOI:10.1007/s40264-020-00973-w